Developing a Novel Prognostic Model to Predict Overall Survival (OS) and 90 Day Mortality Rate (90DM) for Metastatic Colorectal Cancer (mCRC) Patients in Phase I Trials

Santiago Aparo; Gopichand Pendurti; Umang H. Shah; Umang Swami; Yijuan Hou; Mohammad Haroon Ghalib; Imran Chaudhary

Developing a Novel Prognostic Model to Predict Overall Survival (OS) and 90 Day Mortality Rate (90DM) for Metastatic Colorectal Cancer (mCRC) Patients in Phase I Trials

Santiago Aparo, Gopichand Pendurti, Umang H. Shah, Umang Swami, Yijuan Hou, Mohammad Haroon Ghalib, Imran Chaudhary

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting
Volume	33
State	Published - 2015

Disciplines

Medicine and Health Sciences

Cite this

Developing a Novel Prognostic Model to Predict Overall Survival (OS) and 90 Day Mortality Rate (90DM) for Metastatic Colorectal Cancer (mCRC) Patients in Phase I Trials. / Aparo, Santiago; Pendurti, Gopichand; Shah, Umang H. et al.
In: Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting, Vol. 33, 2015.

Research output: Contribution to journal › Article › peer-review

@article{108749a3eab24384a697dcd44fd5485d,

title = "Developing a Novel Prognostic Model to Predict Overall Survival (OS) and 90 Day Mortality Rate (90DM) for Metastatic Colorectal Cancer (mCRC) Patients in Phase I Trials",

author = "Santiago Aparo and Gopichand Pendurti and Shah, \{Umang H.\} and Umang Swami and Yijuan Hou and Ghalib, \{Mohammad Haroon\} and Imran Chaudhary",

note = "e14618 Background: Phase I trials are a critical component of drug development. It is vital to select patients who are most likely to benefit. Prognostic scores like Royal Marsden hospital (RMH), Prince Margaret hospital index (PMHI), Hammersmith score (HS) use low albumin (alb), high LDH, > 2 metastatic sites, ECOG PS, and low sodium to predict the 90DM and OS on trials.",

year = "2015",

language = "American English",

volume = "33",

journal = "Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting",

}

TY - JOUR

T1 - Developing a Novel Prognostic Model to Predict Overall Survival (OS) and 90 Day Mortality Rate (90DM) for Metastatic Colorectal Cancer (mCRC) Patients in Phase I Trials

AU - Aparo, Santiago

AU - Pendurti, Gopichand

AU - Shah, Umang H.

AU - Swami, Umang

AU - Hou, Yijuan

AU - Ghalib, Mohammad Haroon

AU - Chaudhary, Imran

N1 - e14618 Background: Phase I trials are a critical component of drug development. It is vital to select patients who are most likely to benefit. Prognostic scores like Royal Marsden hospital (RMH), Prince Margaret hospital index (PMHI), Hammersmith score (HS) use low albumin (alb), high LDH, > 2 metastatic sites, ECOG PS, and low sodium to predict the 90DM and OS on trials.

PY - 2015

Y1 - 2015

UR - https://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.e14618

M3 - Article

VL - 33

JO - Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting

JF - Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting

ER -

Developing a Novel Prognostic Model to Predict Overall Survival (OS) and 90 Day Mortality Rate (90DM) for Metastatic Colorectal Cancer (mCRC) Patients in Phase I Trials

Disciplines

Other files and links

Cite this